Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 492

1.

The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement.

Otoukesh S, Zhang J, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V, Aldoss I.

Leuk Lymphoma. 2020 Mar 19:1-4. doi: 10.1080/10428194.2020.1742908. [Epub ahead of print] No abstract available.

PMID:
32191144
2.

Requirement of GTP binding for TIF-90-regulated ribosomal RNA synthesis and oncogenic activities in human colon cancer cells.

Nguyen DQ, Hoang DH, Nelson M, Nigam L, Nguyen VTT, Zhang L, Pham TKT, Ho HD, Nguyen DDT, Lam TQ, Tat TT, Elhajmoussa Y, Ly QT, Pichiorri F, Pullarkat V, Zhang B, Kuo YH, Marcucci G, Nguyen LXT.

J Cell Physiol. 2020 Mar 11. doi: 10.1002/jcp.29661. [Epub ahead of print]

PMID:
32159236
3.

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.

Marcucci G, Geyer S, Laumann K, Zhao W, Bucci D, Uy GL, Blum W, Eisfeld AK, Pardee TS, Wang ES, Stock W, Kolitz JE, Kohlschmidt J, Mrózek K, Bloomfield CD, Stone RM, Larson RA.

Blood Adv. 2020 Feb 25;4(4):696-705. doi: 10.1182/bloodadvances.2019000492.

4.

Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.

Pagel JM, Othus M, Garcia-Manero G, Fang M, Radich JP, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Spellman SR, Confer DL, Chell JW, Brown M, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Bayer RL, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Erba HP, Appelbaum FR.

JCO Oncol Pract. 2020 Jan 27:JOP1900133. doi: 10.1200/JOP.19.00133. [Epub ahead of print]

PMID:
32048933
5.

Phase I study of AR-42 and decitabine in acute myeloid leukemia.

Liva SG, Coss CC, Wang J, Blum W, Klisovic R, Bhatnagar B, Walsh K, Geyer S, Zhao Q, Garzon R, Marcucci G, Phelps MA, Walker AR.

Leuk Lymphoma. 2020 Feb 8:1-9. doi: 10.1080/10428194.2020.1719095. [Epub ahead of print]

PMID:
32037935
6.

Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Salhotra A, Yang D, Mokhtari S, Malki MMA, Ali H, Sandhu KS, Aribi A, Khaled S, Mei M, Budde E, Snyder D, Cao T, Spielberger R, Marcucci G, Pullarkat V, Forman SJ, Nakamura R, Stein A, Aldoss I.

Biol Blood Marrow Transplant. 2020 Feb 5. pii: S1083-8791(20)30062-8. doi: 10.1016/j.bbmt.2020.01.029. [Epub ahead of print]

PMID:
32035275
7.

Blueberry Juice Antioxidants Protect Osteogenic Activity against Oxidative Stress and Improve Long-Term Activation of the Mineralization Process in Human Osteoblast-Like SaOS-2 Cells: Involvement of SIRT1.

Domazetovic V, Marcucci G, Falsetti I, Bilia AR, Vincenzini MT, Brandi ML, Iantomasi T.

Antioxidants (Basel). 2020 Feb 1;9(2). pii: E125. doi: 10.3390/antiox9020125.

8.

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.

Döhner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, Prior TW, Marcucci G, Jones D, Krauter J, Heuser M, Voso MT, Ottone T, Nomdedeu JF, Mandrekar SJ, Klisovic RB, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte T, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Benner A, Pallaud C, Stone RM, Döhner H, Bloomfield CD.

Blood. 2020 Jan 30;135(5):371-380. doi: 10.1182/blood.2019002697.

PMID:
31826241
9.

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.

Aldoss I, Dadwal S, Zhang J, Tegtmeier B, Mei M, Arslan S, Al Malki MM, Salhotra A, Ali H, Aribi A, Sandhu K, Khaled S, Snyder D, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Blood Adv. 2019 Dec 10;3(23):4043-4049. doi: 10.1182/bloodadvances.2019000930.

10.

Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo.

Su YL, Wang X, Mann M, Adamus TP, Wang D, Moreira DF, Zhang Z, Ouyang C, He X, Zhang B, Swiderski PM, Forman SJ, Baltimore D, Li L, Marcucci G, Boldin MP, Kortylewski M.

Blood. 2020 Jan 16;135(3):167-180. doi: 10.1182/blood.2019002045.

PMID:
31805184
11.

Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL.

Rodriguez S, Abundis C, Boccalatte F, Mehrotra P, Chiang MY, Yui MA, Wang L, Zhang H, Zollman A, Bonfim-Silva R, Kloetgen A, Palmer J, Sandusky G, Wunderlich M, Kaplan MH, Mulloy JC, Marcucci G, Aifantis I, Cardoso AA, Carlesso N.

Leukemia. 2019 Nov 26. doi: 10.1038/s41375-019-0653-z. [Epub ahead of print]

PMID:
31772299
12.

Topological control of extreme waves.

Marcucci G, Pierangeli D, Agranat AJ, Lee RK, DelRe E, Conti C.

Nat Commun. 2019 Nov 8;10(1):5090. doi: 10.1038/s41467-019-12815-0.

13.

Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia.

Dou L, Yan F, Pang J, Zheng D, Li D, Gao L, Wang L, Xu Y, Shi J, Wang Q, Zhou L, Shen N, Singh P, Wang L, Li Y, Gao Y, Liu T, Chen C, Al-Kali A, Litzow MR, Chi YI, Bode AM, Liu C, Huang H, Liu D, Marcucci G, Liu S, Yu L.

Nat Commun. 2019 Nov 7;10(1):5051. doi: 10.1038/s41467-019-12960-6.

14.

Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis.

Gupta R, Jamal F, Yang D, Chendri C, Aldoss I, Malki MA, Mei M, Salhotra A, Dobrin S, Tran M, Venkataraman K, Palmer J, Stein AS, Sandhu K, Khaled S, Aribi A, Marcucci G, Forman SJ, Snyder D, Nakamura R, Ali H, Pullarkat V.

Bone Marrow Transplant. 2019 Nov 6. doi: 10.1038/s41409-019-0741-8. [Epub ahead of print]

PMID:
31695170
15.

More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine.

Aldoss I, Marcucci G.

Chin Clin Oncol. 2019 Oct;8(S1):S25. doi: 10.21037/cco.2019.09.03. No abstract available.

16.

Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance).

Klepin HD, Ritchie E, Major-Elechi B, Le-Rademacher J, Seisler D, Storrick L, Sanford BL, Marcucci G, Zhao W, Geyer SA, Ballman KV, Powell BL, Baer MR, Stock W, Cohen HJ, Stone RM, Larson RA, Uy GL.

J Geriatr Oncol. 2020 Jan;11(1):107-113. doi: 10.1016/j.jgo.2019.10.002. Epub 2019 Oct 24.

PMID:
31668825
17.

Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.

Nakamura R, Gendzekhadze K, Palmer J, Tsai NC, Mokhtari S, Forman SJ, Zaia JA, Senitzer D, Marcucci G, Stein A.

Leuk Res. 2019 Dec;87:106230. doi: 10.1016/j.leukres.2019.106230. Epub 2019 Sep 28.

PMID:
31644966
18.

MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages.

Khalife J, Ghose J, Martella M, Viola D, Rocci A, Troadec E, Terrazas C, Satoskar AR, Gunes EG, Dona A, Sanchez JF, Bergsagel PL, Chesi M, Pozhitkov A, Rosen S, Marcucci G, Keats JJ, Hofmeister CC, Krishnan A, Caserta E, Pichiorri F.

JCI Insight. 2019 Nov 1;4(21). pii: 129348. doi: 10.1172/jci.insight.129348.

19.

Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center.

Salhotra A, Hui S, Yang D, Mokhtari S, Mei M, Al Malki MM, Aldoss I, Ali H, Sandhu KS, Aribi A, Khaled S, Dandapani S, Peng K, Teh JB, Murata-Collins J, Budde E, Dadwal S, Pullarkat V, Snyder D, Spielberger R, Wong J, Armenian S, Marcucci G, Forman SJ, Nakamura R, Stein A.

Biol Blood Marrow Transplant. 2020 Feb;26(2):292-299. doi: 10.1016/j.bbmt.2019.09.017. Epub 2019 Sep 16.

PMID:
31536825
20.

Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.

Aldoss I, Zhang J, Pillai R, Shouse G, Sanchez JF, Mei M, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Br J Haematol. 2019 Oct;187(2):e45-e48. doi: 10.1111/bjh.16166. Epub 2019 Aug 22. No abstract available.

PMID:
31441045
21.

Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.

Zhu Y, He X, Lin YC, Dong H, Zhang L, Chen X, Wang Z, Shen Y, Li M, Wang H, Sun J, Nguyen LX, Zhang H, Jiang W, Yang Y, Chen J, Müschen M, Chen CW, Konopleva MY, Sun W, Jin J, Carlesso N, Marcucci G, Luo Y, Li L.

Blood. 2019 Oct 10;134(15):1257-1268. doi: 10.1182/blood.2019002457.

PMID:
31395602
22.

The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.

Otoukesh S, Salhotra A, Marcucci G, Forman SJ, Pullarkat V, Aldoss I.

Leuk Res. 2019 Sep;84:106196. doi: 10.1016/j.leukres.2019.106196. Epub 2019 Jul 30. No abstract available.

PMID:
31377457
23.

Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.

Wang H, Zhao D, Nguyen LX, Wu H, Li L, Dong D, Troadec E, Zhu Y, Hoang DH, Stein AS, Al Malki M, Aldoss I, Lin A, Ghoda LY, McDonald T, Pichiorri F, Carlesso N, Kuo YH, Zhang B, Jin J, Marcucci G.

Leukemia. 2020 Jan;34(1):75-86. doi: 10.1038/s41375-019-0522-9. Epub 2019 Jul 23.

PMID:
31337857
24.

Large-Scale Photonic Ising Machine by Spatial Light Modulation.

Pierangeli D, Marcucci G, Conti C.

Phys Rev Lett. 2019 May 31;122(21):213902. doi: 10.1103/PhysRevLett.122.213902.

PMID:
31283311
25.

Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Aldoss I, Yang D, Pillai R, Sanchez JF, Mei M, Aribi A, Ali H, Sandhu K, Al Malki MM, Salhotra A, Khaled S, Sun W, O'Donnell M, Snyder D, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.

Am J Hematol. 2019 Oct;94(10):E253-E255. doi: 10.1002/ajh.25567. Epub 2019 Jul 10. No abstract available.

PMID:
31259427
26.

PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ acute myeloid leukemia.

He X, Zhu Y, Lin YC, Li M, Du J, Dong H, Sun J, Zhu L, Wang H, Ding Z, Zhang L, Zhang L, Zhao D, Wang Z, Wu H, Zhang H, Jiang W, Xu Y, Jin J, Shen Y, Perry J, Zhao X, Zhang B, Liu S, Xue SL, Shen B, Chen CW, Chen J, Khaled S, Kuo YH, Marcucci G, Luo Y, Li L.

Blood. 2019 Aug 8;134(6):548-560. doi: 10.1182/blood.2019001282. Epub 2019 Jun 19.

PMID:
31217189
27.

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM; OCN, Hammond L, Ogba N.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):721-749. doi: 10.6004/jnccn.2019.0028.

PMID:
31200351
28.

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614).

Yin J, LaPlant B, Uy GL, Marcucci G, Blum W, Larson RA, Stone RM, Mandrekar SJ.

Blood Adv. 2019 Jun 11;3(11):1714-1721. doi: 10.1182/bloodadvances.2018026112.

29.

Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.

Salhotra A, Afkhami M, Yang D, Mokhtari S, Telatar M, Gu D, Pillai RK, Weisenburger DD, Murata-Collins J, Weigel D, Aoun P, Aldoss I, Al Malki MM, Khaled S, Mei M, Ali H, Aribi A, Budde E, Sandhu K, O'Donnell M, Snyder D, Pullarkat V, Forman SJ, Marcucci G, Nakamura R, Stein A.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e400-e405. doi: 10.1016/j.clml.2019.04.007. Epub 2019 Apr 26.

PMID:
31155409
30.

ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.

Chiang CL, Goswami S, Frissora FW, Xie Z, Yan PS, Bundschuh R, Walker LA, Huang X, Mani R, Mo XM, Baskar S, Rader C, Phelps MA, Marcucci G, Byrd JC, Lee LJ, Muthusamy N.

Blood. 2019 Aug 1;134(5):432-444. doi: 10.1182/blood.2018882290. Epub 2019 May 31.

PMID:
31151986
31.

Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors.

Marcucci G, Beltrami G, Tamburini A, Body JJ, Confavreux CB, Hadji P, Holzer G, Kendler D, Napoli N, Pierroz DD, Rizzoli R, Brandi ML.

Ann Oncol. 2019 Jun 1;30(6):908-920. doi: 10.1093/annonc/mdz120.

PMID:
31111878
32.

Targeted Delivery of miRNA Antagonists to Myeloid Cells In Vitro and In Vivo.

Su YL, Swiderski P, Marcucci G, Kortylewski M.

Methods Mol Biol. 2019;1974:141-150. doi: 10.1007/978-1-4939-9220-1_10.

PMID:
31099000
33.

Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia.

Aldoss I, Nakamura R, Yang D, Salhotra A, Stein AS, Pullarkat V, Forman SJ, Marcucci G.

Bone Marrow Transplant. 2020 Feb;55(2):473-475. doi: 10.1038/s41409-019-0553-x. Epub 2019 May 14. No abstract available.

PMID:
31089274
34.

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.

Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, Zhang MJ, Storrick E, Lafky JM, Chow S, Mrózek K, Attar EC, Nand S, Bloomfield CD, Cripe LD, Tallman MS, Appelbaum F, Larson RA, Marcucci G, Roboz GJ, Uy GL, Stone RM, Jatoi A, Shea TC, de Lima M, Foran JM, Sandmaier BM, Litzow MR, Erba HP, Hurria A, Weisdorf DJ, Artz AS.

Leukemia. 2019 Nov;33(11):2599-2609. doi: 10.1038/s41375-019-0477-x. Epub 2019 May 9.

35.

Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing.

Slavin TP, Coffee B, Bernhisel R, Logan J, Cox HC, Marcucci G, Weitzel J, Neuhausen SL, Mancini-DiNardo D.

Cancer Genet. 2019 Jun;235-236:31-38. doi: 10.1016/j.cancergen.2019.04.005. Epub 2019 Apr 13.

36.

Blueberry juice protects osteocytes and bone precursor cells against oxidative stress partly through SIRT1.

Domazetovic V, Marcucci G, Pierucci F, Bruno G, Di Cesare Mannelli L, Ghelardini C, Brandi ML, Iantomasi T, Meacci E, Vincenzini MT.

FEBS Open Bio. 2019 Jun;9(6):1082-1096. doi: 10.1002/2211-5463.12634. Epub 2019 Apr 20.

37.

Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting.

Buettner R, Morales C, Caserta E, Troadec E, Gunes EG, Viola D, Khalife J, Li H, Keats JJ, Christofferson A, Wu X, Synold TW, Palmer J, Sanchez JF, Pozhitkov A, Vaidehi N, Marcucci G, Krishnan A, Rosenzweig MA, Pichiorri F, Rosen ST.

Blood Adv. 2019 Apr 9;3(7):1027-1032. doi: 10.1182/bloodadvances.2018027227. No abstract available.

38.

Ebp1 p48 promotes oncogenic activities in human colon cancer cells through regulation of TIF-90-mediated ribosomal RNA synthesis.

Nguyen DQ, Hoang DH, Nguyen TTV, Ho HD, Huynh V, Shin JH, Ly QT, Thi Nguyen DD, Ghoda L, Marcucci G, Nguyen LXT.

J Cell Physiol. 2019 Aug;234(10):17612-17621. doi: 10.1002/jcp.28385. Epub 2019 Feb 22.

PMID:
30793766
39.

8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia.

Buettner R, Nguyen LXT, Kumar B, Morales C, Liu C, Chen LS, Pemovska T, Synold TW, Palmer J, Thompson R, Li L, Hoang DH, Zhang B, Ghoda L, Kowolik C, Kontro M, Leitch C, Wennerberg K, Yu X, Chen CC, Horne D, Gandhi V, Pullarkat V, Marcucci G, Rosen ST.

J Cell Physiol. 2019 Feb 15. doi: 10.1002/jcp.28294. [Epub ahead of print]

PMID:
30770553
40.

Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.

Hughes JH, Phelps MA, Upton RN, Reuter SE, Gao Y, Byrd JC, Grever MR, Hofmeister CC, Marcucci G, Blum W, Blum KA, Foster DJR.

Br J Clin Pharmacol. 2019 May;85(5):924-934. doi: 10.1111/bcp.13873. Epub 2019 Feb 27.

PMID:
30672004
41.

Clinical presentation and management of hypoparathyroidism.

Marcucci G, Cianferotti L, Brandi ML.

Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):927-939. doi: 10.1016/j.beem.2018.09.007. Epub 2018 Sep 28. Review.

PMID:
30665553
42.

Causes and pathophysiology of hypoparathyroidism.

Cianferotti L, Marcucci G, Brandi ML.

Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):909-925. doi: 10.1016/j.beem.2018.07.001. Epub 2018 Jul 29. Review.

PMID:
30665552
43.

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA.

Blood. 2019 Apr 4;133(14):1548-1559. doi: 10.1182/blood-2018-10-881961. Epub 2019 Jan 18. Erratum in: Blood. 2019 Sep 26;134(13):1111.

PMID:
30658992
44.

Conventional Treatment of Hypoparathyroidism.

Marcucci G, Brandi ML.

Front Horm Res. 2019;51:160-164. doi: 10.1159/000491046. Epub 2018 Nov 19. Review.

PMID:
30641530
45.

A New Era for Chronic Management of Hypoparathyroidism: Parathyroid Hormone Peptides.

Marcucci G, Brandi ML.

Front Horm Res. 2019;51:165-171. doi: 10.1159/000491047. Epub 2018 Nov 19. Review.

PMID:
30641529
46.

The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.

Nguyen LXT, Troadec E, Kalvala A, Kumar B, Hoang DH, Viola D, Zhang B, Nguyen DQ, Aldoss I, Ghoda L, Budde E, Pichiorri F, Rosen S, Forman SJ, Marcucci G, Pullarkat V.

J Cell Physiol. 2019 Aug;234(8):14040-14049. doi: 10.1002/jcp.28091. Epub 2019 Jan 8.

PMID:
30623427
47.

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Ali H, Aldoss I, Yang D, Mokhtari S, Khaled S, Aribi A, Afkhami M, Al Malki MM, Cao T, Mei M, O'Donnell M, Salhotra A, Pullarkat V, Yang L, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pillai R, Snyder D.

Blood Adv. 2019 Jan 8;3(1):83-95. doi: 10.1182/bloodadvances.2018026658.

48.

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).

Roboz GJ, Mandrekar SJ, Desai P, Laumann K, Walker AR, Wang ES, Kolitz JE, Powell BL, Attar EC, Stock W, Bloomfield CD, Kohlschmidt J, Mrózek K, Hassane DC, Garraway L, Jané-Valbuena J, Baltay M, Tracy A, Marcucci G, Stone RM, Larson RA.

Blood Adv. 2018 Dec 26;2(24):3608-3617. doi: 10.1182/bloodadvances.2018023689.

49.

Calcium Intake in Bone Health: A Focus on Calcium-Rich Mineral Waters.

Vannucci L, Fossi C, Quattrini S, Guasti L, Pampaloni B, Gronchi G, Giusti F, Romagnoli C, Cianferotti L, Marcucci G, Brandi ML.

Nutrients. 2018 Dec 5;10(12). pii: E1930. doi: 10.3390/nu10121930. Review.

50.

Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.

Mei M, Aldoss I, Marcucci G, Pullarkat V.

Am J Hematol. 2019 Mar;94(3):358-362. doi: 10.1002/ajh.25369. Epub 2018 Dec 13. Review.

Supplemental Content

Loading ...
Support Center